Valuation: Profound Medical Corp

Market Cap 306M 220M 191M 180M 163M 21.09B 308M 2.15B 828M 10.7B 826M 808M 34.01B P/E 2026 *
-6.99x
P/E 2027 * -10.3x
Enterprise Value 306M 220M 191M 180M 163M 21.09B 308M 2.15B 828M 10.7B 826M 808M 34.01B EV / Sales 2026 *
8.45x
EV / Sales 2027 * 5.15x
Free-Float
95.94%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 59 01/09/2026
Director of Finance/CFO - 14/08/2026
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.98%+28.34%+18.09% 225B
+0.84%-2.23%+6.42%-20.84% 141B
+1.82%+6.78%-13.84%+23.10% 130B
+4.26%-0.48%-55.18%-15.41% 62.29B
+1.99%+0.96%-18.45%-13.93% 49.39B
+1.20%-1.45%+12.37%+15.46% 48.63B
-0.66%-0.91%+15.82%+26.66% 41.42B
-1.12%-0.08%+34.63%+48.01% 40.12B
+2.12%+0.65%-17.96%+50.70% 31.23B
Average +1.13%-3.23%-0.87%+14.65% 85.52B
Weighted average by Cap. +0.98%-2.40%+4.19%+10.23%

Financials

2026 *2027 *
Net sales 36.22M 26.02M 22.55M 21.28M 19.31M 2.49B 36.48M 254M 97.93M 1.27B 97.74M 95.59M 4.02B 59.46M 42.72M 37.02M 34.94M 31.69M 4.09B 59.89M 417M 161M 2.08B 160M 157M 6.6B
Net income -44.08M -31.67M -27.45M -25.9M -23.5M -3.04B -44.4M -309M -119M -1.54B -119M -116M -4.9B -31.27M -22.47M -19.47M -18.37M -16.67M -2.15B -31.49M -219M -84.55M -1.09B -84.38M -82.52M -3.47B
Net Debt - -
Logo Profound Medical Corp
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!